131 related articles for article (PubMed ID: 37527782)
21. Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis.
Dawwas GK; Dietrich E; Smith SM; Davis K; Park H
Clin Ther; 2020 Sep; 42(9):e161-e176. PubMed ID: 32768247
[TBL] [Abstract][Full Text] [Related]
22. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies.
Guan T; Laguna A; Soares A; Legasto CS; Block S; Saunders IM; Alvarez K; Pon T; Patel N; Mahajan A; Lee A
J Thromb Thrombolysis; 2023 Oct; 56(3):439-446. PubMed ID: 37421494
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of the Risk Factors Associated with Minor Bleeding in Patients with Venous Thromboembolism during Treatment with Direct Oral Anticoagulants].
Sunaga T; Shimizu T; Nakamura S; Takahashi N; Higashino M; Matsui M; Hozumi T; Ebato M; Suzuki H; Kogo M; Watanabe T; Sasaki T
Yakugaku Zasshi; 2019; 139(3):461-467. PubMed ID: 30828024
[TBL] [Abstract][Full Text] [Related]
26. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis.
Mulder FI; Bosch FTM; Young AM; Marshall A; McBane RD; Zemla TJ; Carrier M; Kamphuisen PW; Bossuyt PMM; Büller HR; Weitz JI; Middeldorp S; van Es N
Blood; 2020 Sep; 136(12):1433-1441. PubMed ID: 32396939
[TBL] [Abstract][Full Text] [Related]
27. Incidence of venous thromboembolism, recurrence, and bleeding after isolated superficial vein thrombosis: findings from the Venous Thrombosis Registry in Østfold Hospital.
Jørgensen CT; Brækkan SK; Førsund E; Pettersen HH; Tjønnfjord E; Ghanima W; Tavoly M
J Thromb Haemost; 2024 Feb; 22(2):526-533. PubMed ID: 37913911
[TBL] [Abstract][Full Text] [Related]
28. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.
Hakoum MB; Kahale LA; Tsolakian IG; Matar CF; Yosuico VE; Terrenato I; Sperati F; Barba M; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD006649. PubMed ID: 29363105
[TBL] [Abstract][Full Text] [Related]
29. Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: An updated meta-analysis of randomized controlled trials.
Haykal T; Zayed Y; Deliwala S; Kerbage J; Ponnapalli A; Malladi S; Goranta S; Samji V; Adam S
Thromb Res; 2020 Oct; 194():57-65. PubMed ID: 32788122
[TBL] [Abstract][Full Text] [Related]
30. Acceptance of a potential major bleeding among patients with venous thromboembolism on long-term oral anticoagulation: the knowledge of the disease and therapy matters.
Konieczyńska M; Kupis RW; Bijak P; Malinowski KP; Undas A
Thromb Res; 2020 Sep; 193():116-121. PubMed ID: 32535233
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: A systematic review and Bayesian network meta-analysis.
Ning H; Yang N; Ding Y; Chen H; Wang L; Han Y; Cheng G; Zou M
Med Clin (Barc); 2023 Mar; 160(6):245-252. PubMed ID: 36031454
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study.
Roberts MZ; Gaskill GE; Kanter-Washko J; Kyle TR; Jones BC; Bohm NM
J Thromb Thrombolysis; 2018 May; 45(4):512-515. PubMed ID: 29556958
[TBL] [Abstract][Full Text] [Related]
33. The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment.
Kooiman J; van Hagen N; Iglesias Del Sol A; Planken EV; Lip GY; van der Meer FJ; Cannegieter SC; Klok FA; Huisman MV
PLoS One; 2015; 10(4):e0122520. PubMed ID: 25905638
[TBL] [Abstract][Full Text] [Related]
34. Risk of major bleeding during extended oral anticoagulation in patients with first unprovoked venous thromboembolism: a systematic review and meta-analysis protocol.
Khan F; Kimpton M; Tritschler T; Le Gal G; Hutton B; Fergusson DA; Rodger MA
Syst Rev; 2019 Oct; 8(1):245. PubMed ID: 31661033
[TBL] [Abstract][Full Text] [Related]
35. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
36. Risk Factors for Major Bleeding During Anticoagulation Therapy in Cancer-Associated Venous Thromboembolism - From the COMMAND VTE Registry.
Nishimoto Y; Yamashita Y; Kim K; Morimoto T; Saga S; Amano H; Takase T; Hiramori S; Oi M; Akao M; Kobayashi Y; Toyofuku M; Izumi T; Tada T; Chen PM; Murata K; Tsuyuki Y; Sasa T; Sakamoto J; Kinoshita M; Togi K; Mabuchi H; Takabayashi K; Yoshikawa Y; Shiomi H; Kato T; Makiyama T; Ono K; Sato Y; Kimura T;
Circ J; 2020 Oct; 84(11):2006-2014. PubMed ID: 33012736
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and safety of anticoagulants among venous thromboembolism cancer patients with and without brain cancer.
Cohen A; Noxon V; Dhamane A; Bruette R; Shah S; Hines DM; Alfred T; Luo X
Thromb Res; 2023 Jun; 226():117-126. PubMed ID: 37146438
[TBL] [Abstract][Full Text] [Related]
38. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
Kraaijpoel N; Di Nisio M; Mulder FI; van Es N; Beyer-Westendorf J; Carrier M; Garcia D; Grosso M; Kakkar AK; Mercuri MF; Middeldorp S; Hernandez CR; Santamaria A; Schwocho L; Segers A; Verhamme P; Wang TF; Weitz JI; Zhang G; Zwicker JI; Büller HR; Raskob GE
Thromb Haemost; 2018 Aug; 118(8):1439-1449. PubMed ID: 30060256
[TBL] [Abstract][Full Text] [Related]
39. A systematic review and meta-analysis for the association between duration of anticoagulation therapy and the risk of venous thromboembolism in patients with lower limb superficial venous thrombosis.
Lobastov K; Dubar E; Schastlivtsev I; Bargandzhiya A
J Vasc Surg Venous Lymphat Disord; 2024 Mar; 12(2):101726. PubMed ID: 38008180
[TBL] [Abstract][Full Text] [Related]
40. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.
Schulman S; Zondag M; Linkins L; Pasca S; Cheung YW; de Sancho M; Gallus A; Lecumberri R; Molnar S; Ageno W; Le Gal G; Falanga A; Hulegårdh E; Ranta S; Kamphuisen P; Debourdeau P; Rigamonti V; Ortel TL; Lee A
J Thromb Haemost; 2015 Jun; 13(6):1010-8. PubMed ID: 25851122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
